158 related articles for article (PubMed ID: 9687333)
1. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
[TBL] [Abstract][Full Text] [Related]
2. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
3. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug.
Mehta SC; Afouna MI; Ghanem AH; Higuchi WI; Kern ER
J Pharm Sci; 1997 Jul; 86(7):797-801. PubMed ID: 9232519
[TBL] [Abstract][Full Text] [Related]
4. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
5. Correlation of in vivo topical efficacies with in vitro predictions using acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice: an evaluation of the predictive value of the C* concept.
Patel PJ; Ghanem AH; Higuchi WI; Srinivasan V; Kern ER
Antiviral Res; 1996 Mar; 29(2-3):279-86. PubMed ID: 8739606
[TBL] [Abstract][Full Text] [Related]
6. Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.
Freeman DJ; Sacks SL; De Clercq E; Spruance SL
Antiviral Res; 1985 Jun; 5(3):169-77. PubMed ID: 2992371
[TBL] [Abstract][Full Text] [Related]
7. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
8. Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice.
Imanidis G; Song WQ; Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1994 Jul; 11(7):1035-41. PubMed ID: 7937545
[TBL] [Abstract][Full Text] [Related]
9. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro.
Liu H; Pan WS; Tang R; Luo SD
Pharmazie; 2004 Mar; 59(3):203-6. PubMed ID: 15074594
[TBL] [Abstract][Full Text] [Related]
10. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.
Bolger GT; Allen T; Garneau M; Lapeyre N; Liard F; Jaramillo J
Antiviral Res; 1997 Aug; 35(3):157-65. PubMed ID: 9298755
[TBL] [Abstract][Full Text] [Related]
11. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T; Lixin W; Takayama-Ito M; Iizuka I; Ogata M; Tsuji M; Nishimura H; Taniguchi S; Morikawa S; Kurane I; Mizuguchi M; Saijo M
Antiviral Res; 2011 Aug; 91(2):142-9. PubMed ID: 21669227
[TBL] [Abstract][Full Text] [Related]
12. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
de Clercq E
Antimicrob Agents Chemother; 1984 Aug; 26(2):155-9. PubMed ID: 6486759
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
14. In vivo quantification of acyclovir exposure in the dermis following iontophoresis of semisolid formulations.
Shukla C; Friden P; Juluru R; Stagni G
J Pharm Sci; 2009 Mar; 98(3):917-25. PubMed ID: 18623192
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
[TBL] [Abstract][Full Text] [Related]
16. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
[TBL] [Abstract][Full Text] [Related]
17. β-l-1-[5-(E-2-bromovinyl)-2-(hydroxymethyl)-1,3-(dioxolan-4-yl)] uracil (l-BHDU) prevents varicella-zoster virus replication in a SCID-Hu mouse model and does not interfere with 5-fluorouracil catabolism.
De C; Liu D; Zheng B; Singh US; Chavre S; White C; Arnold RD; Hagen FK; Chu CK; Moffat JF
Antiviral Res; 2014 Oct; 110():10-9. PubMed ID: 25051026
[TBL] [Abstract][Full Text] [Related]
18. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication.
Lin JC; Machida H
Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
